Supriya Lifescience IPO ends with robust subscription
21-Dec-21   11:07 Hrs IST

The initial public offer (IPO) of Supriya Lifescience received bids for 1,03,89,66,318 shares as against 1,45,28,299 shares on offer. The issue was subscribed 71.51 times.

The non institutional investors category was subscribed 161.22 times. The retail investors category was subscribed 56.01 times. The qualified institutional buyers category was subscribed 31.83 times.

The issue opened for bidding on 16 December 2021 and it closed on 20 December 2021. The price band of the IPO was fixed at Rs 265-274 per share.

Ahead of the IPO, the company on 15 December 2021, finalized allocation of 1,14,96,351 equity shares to anchor investors at an allocation price of Rs 274 per share, aggregating to Rs 315 crore.

The IPO comprised of fresh issue of equity shares worth up to Rs 200 crore and an offer for sale of Rs 500 crore by existing shareholders.

Satish Waman Wagh, the promoter of the company, currently holds an aggregate of 7,26,42,390 equity shares, aggregating to 99.26% of the pre-offer issued share capital. The post IPO shareholding for the same is expected to be around 68.24%.

The objectives for the fresh issue are funding capital expenditure requirements of Rs 92.3 crore, Rs 60 crore for repayment/pre-payment, in full or part of borrowings and remaining amount will be used for general corporate purposes.

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. As of 31 October 2021, the company has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anesthetics, vitamin, anti-asthmatic and antiallergic.

The business operations of the company are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra, which is approximately 250 km from Mumbai. Its manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to the products being exported to the relevant jurisdictions.

The manufacturing facility is spread across 23,806, having reactor capacity of 332 KL/ day and seven cleanrooms. In addition, company has acquired a plot of land, admeasuring 12,551, near the present manufacturing facility, wherein the Company intends to expand its manufacturing infrastructure.

The company intends to continue to drive R&D initiatives towards the development of innovative APIs. It also intends to improve its R&D capabilities, with a focus on capturing more high-value first-to-market opportunities in key international markets, as well as leveraging broad product basket to enhance market position globally.

The company reported a net profit of Rs 65.96 crore on sales of Rs 224.80 crore in six month ended September 2021.

Powered by Capital Market - Live News

Attention Investors:
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. Prevent Unauthorized Transactions in your Demat account\Trading account: Update your Mobile Number with your Depository Participant\Exchange. Receive alerts on your Registered Mobile for all debit and other important transactions in your Demat account\Trading account directly from Depository\Exchange on the same day.........issued in the interest of investors.
The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.
Disclosure of Proprietary Account Trading by Members to Clients
Proprietary Trading Disclosure:In terms of provisions of the Rules, Bye-Laws and Business Rules of the Exchange and with reference to circular MCX/T&S/147/2016 dated May 17, 2016 regarding Disclosure of Proprietary Account Trading by broker to client.,Pursuant to SEBI Circular Number SEBI/MRD/SEC/Cir-42/2003 dated November 19, 2003 & SEBI/HO/CDMRD/DMP/CIR/P/2016/49 dated April 25, 2016 GOODWILL WEALTH MANAGEMENT PVT LTD. Discloses to its clients about its policies on proprietary trades.
Copyright © 2016 All rights Reserved GOODWILL
Designed, Developed and content powered by CMOTS Infotech ( ISO 9001:2015 certified )
Filing complaints on SEBI Complaint Redress System (SCORES)
– Easy & quick
  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name, PAN, Address, Mobile Number, E-mail ID.
  • Benefits:
    • Effective communication
    • Speedy redressal of the grievances.
You can file complaints on SCORES through